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Background: Regular anti-malarial therapy in pregnancy, a pillar of malaria control, may affect malaria immunity,
with therapeutic implications in regions of reducing transmission.
Methods: Plasma antibodies to leading vaccine candidate merozoite antigens and opsonizing antibodies to
endothelial-binding and placental-binding infected erythrocytes were quantified in pregnant Melanesian women
receiving sulfadoxine-pyrimethamine (SP) with chloroquine taken once, or three courses of SP with azithromycin.
Results: Malaria prevalence was low. Between enrolment and delivery, antibodies to recombinant antigens
declined in both groups (p < 0.0001). In contrast, median levels of opsonizing antibodies did not change, although
levels for some individuals changed significantly. In multivariate analysis, the malaria prevention regimen did not
influence antibody levels.
Conclusion: Different preventive anti-malarial chemotherapy regimens used during pregnancy had limited impact
on malarial-immunity in a low-transmission region of Papua New Guinea.
Trial registrations: NCT01136850
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Pregnant women are susceptible to Plasmodium falcip-
arum infection, and malaria in pregnancy (MiP) increases
the risks for mother and baby [1]. Antibody to placental-
binding infected erythrocytes (IEs) can protect against
MiP and its consequences [2, 3]. Intermittent preventive
therapy during pregnancy (IPTp) and insecticide-treated
bed nets (ITN) can reduce the impact of MiP [4], but
could impair development of pregnancy-associated im-
munity [5]. Current data on the impact of malaria preven-
tion on the acquisition of pregnancy-associated malarial
antibodies is largely restricted to African settings. It was
hypothesized that multiple courses of IPTp during preg-
nancy may be associated with impaired development of* Correspondence: andrew.teo@uqconnect.edu.au
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unless otherwise stated.pregnancy-associated malaria immunity, and this was
tested in a cohort of pregnant women from Madang,
Papua New Guinea (PNG).
Methods
Ethics approval
Ethics approval was obtained from the PNG Institute of
Medical Research’s Institutional Review Board (08.15),
the PNG Medical Research Advisory Council (05.03,
10.50) and the Human Research Ethics Committee of
Melbourne Health (2001.016, 2008.162). Women pro-
vided written informed consent.
Study participants
Pregnant women were recruited for a malaria prevention
trial in Madang, PNG, and plasma samples from a sub-
set of these women were used in this study [6]. Par-
ticipants recruited at first antenatal visit (ANC) wereis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pyrimethamine (SP) with chloroquine (CQ) (N = 304),
control arm, or up to three courses of SP and azithro-
mycin (AZ) (N = 277), intervention arm, and followed to
delivery. Women were given an ITN, if available, and
usage was recorded. Paired plasma samples collected at
enrolment and delivery were assayed for P. falciparum
antibodies.Malariometric indices
Presence of P. falciparum infection (enrolment, delivery)
was determined by light microscopy (LMS) and quanti-
tative polymerase chain reaction (qPCR) of peripheral
blood films, from placental impression (LMS, qPCR),
and by examination of placental histology. Placental mal-
aria was classified as acute, chronic or past infection [7].Parasite and cell cultures
The laboratory-adapted P. falciparum lines CS2 (placental-
binding) and E8B-ICAM (endothelial-binding), and THP-1
monocyte-like cells, were cultured as described [8].Assays of IgG to schizont extract, merozoite antigens and
measles haemagglutinin
Samples were assayed for immunoglobulin G (IgG) anti-
bodies to recombinant P. falciparum antigens and measles
haemagglutinin protein by enzyme-linked immunosorbent
assay (ELISA) as described [8]. In brief, microtitre plates
were coated with schizont extract from CS2 (1/2000),
MSP2 from FC27 (0.5 μg/ml), MSP3 from 3D7 full ecto-
domain (2 μg/ml), PfRH2 from 3D7 (0.5 μg/ml) and mea-
sles haemagglutinin (1 μg/ml; Abcam, Melbourne, VIC,
Australia). Test plasma (1/1000, in duplicate) was added,
followed by incubation with peroxidase-conjugated goat
anti-human IgG (1/2500; Merck Millipore, Kilsyth, VIC,
Australia). The reaction was developed and optical density
was determined at 405 nm.Phagocytosis of infected erythrocytes
The level of opsonizing IgG antibody was determined as
before [8]. In brief, 30 μL of purified trophozoite-stage
IEs were stained with ethidium bromide, and opsonized
with 3.3 μl of plasma for 1 h, followed by incubation
with THP-1 cells for 40 min. Phagocytosis was stopped
and unphagocytosed IEs were lysed, followed by fixing
the THP-1 cells in 2 % (w/v) paraformaldehyde. The
cells were acquired using a HyperCyt® CyAn flow cyt-
ometer (Beckman Coulter). Data are represented as per-
centage of THP-1 cells containing ingested IEs. For all
assays, plasma from six adults with no history of malaria
exposure was included. Discordant samples were re-run,
using published rules [9].Antibody responses during pregnancy
To assess changes during pregnancy, the mean antibody
levels from paired samples collected at enrolment and
delivery were compared, and the same rules were ap-
plied as described [8]. In brief, samples were categorized
based on their adjusted mean variance: 1) <20 % with
mean difference of <10 %, no change; 2) >20 % with
mean difference of >10 %, either decrease or increase in
antibody responses.Statistical analysis
The main interest of analysis is whether preventive ther-
apies during pregnancy had an impact on development of
pregnancy related anti-malarial antibodies. Data were ana-
lysed with Stata version 13.0 (StataCorp) and GraphPad
Prism v5 (GraphPad Software, Inc). Differences in po-
pulation mean ranks of paired continuous non-parametric
variables, antibody responses, were evaluated using the
Wilcoxon signed-rank test. Categorical variables were
compared using the χ2 tests. Multiple linear regression
analysis was performed to determine associations between
continuous and categorical variables on antibody, and ad-
justed analyses included treatment arms, maternal charac-
teristics, and interaction variables.Results
Patient characteristics
Participant characteristics (SP-CQ n = 304, SP-AZ n = 277)
were similar between groups. Most women receiving
SP-AZ (82 %) had three courses. The prevalence of malaria
infection was low at enrolment and delivery (Table 1).Antibody to recombinant antigens
Median antibody levels to schizont extract and mero-
zoite antigens did not differ by treatment arm at delivery
(schizont extract z = −0.4, PfRh2 z = −0.8, MSP2 z = 0.2,
MSP3 z = −0.3, all p > 0.05). There was a significant de-
cline in median level of antibodies against schizont ex-
tract, MSP2, MSP3 and PfRh2 between enrolment and
delivery (all p < 0.0001) in both treatment arms. Antibody
to measles haemagglutinin (control) showed a similar sig-
nificant decline in both treatment arms (Fig. 1a).Opsonizing antibody to infected erythrocytes
Opsonizing antibodies to placental-binding and-endothelial-
binding IEs did not vary by treatment arm at delivery
(CS2 z = −0.8, E8B-ICAM z = 0.6, both p > 0.05). In con-
trast to decline in antibodies to recombinant antigens
(above), median levels of opsonizing antibodies to both
placental-binding and-endothelial-binding IEs did not
change significantly between enrolment and delivery in
either treatment arm (Fig. 1b).
Table 1 Study population characteristics of Papua New
Guinean women
Characteristic Single course
of CQ and SP
treatment
(n = 304)
Three courses
of SP and AZ
treatment
(n = 277)
P-value
Age, years 24.0 (21.0–28.0) 24.0 (21.0–28.0) 0.2
Weight at enrolment, kg 55.0 (50.0–59.0) 53.0 (49.0–59.0) 0.6
MUAC at enrolment, cm 23.0 (22.0–25.0) 23.0 (22.0–25.0) 0.5
Gravidity 0.4
Gravida 1, n (%) 108 (35.5) 92 (33.2)
Gravida 2, n (%) 91 (29.9) 88 (31.8)
Gravida 3, n (%) 105 (34.5) 97 (35.0)
Overall Bed net use 0.4
No, n (%) 2 (0.7) 0 (0.0)
Intermittent, n (%) 89 (29.3) 82 (29.6)
Regular, n (%) 213 (70.1) 195 (70.4)
Ethnicity 0.5
Madang/Morobe 194 (63.8) 193 (69.7)
Sepik 57 (18.8) 41 (14.8)
Highland 26 (8.6) 19 (6.9)
Others 27 (8.9) 24 (8.7)
Residence 0.9
Urban 51 (16.8) 44 (16.0)
Peri-urban 59 (19.5) 50 (18.1)
Rural 181 (59.7) 170 (61.8)
Migrant 12 (4.0) 11 (4.0)
Light microscopy (P.
falciparum)
Enrolment (peripheral blood) 20 (6.6) 15 (5.4) 0.5
Delivery (peripheral blood) 7 (2.3) 5 (1.8) 0.7
Delivery (placental blood) 7 (2.3) 4 (1.4) 0.2
qPCR (P. falciparum)
Enrolment (peripheral blood) 31 (10.2) 24 (8.7) 0.8
Delivery (peripheral blood) 14 (4.6) 8 (2.9) 0.1
Delivery (placental blood) 7 (2.3) 1 (0.3) 0.1
Placental histology 0.1
Uninfected 171 (81.8) 170 (81.0)
Infecteda 38 (18.2) 40 (19.1)
Data represented as median and interquartile range, unless otherwise indicated
AZ azithromycin, CQ chloroquine, SP sulfadoxine-pyrimethamine,
MUAC mid-upper arm circumference
aPlacental malaria was defined as histological evidence of acute, chronic, or
past infection
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arm between enrolment and delivery
When differences in individual responses were com-
pared between enrolment and delivery, for each treat-
ment arm, similar numbers of women experiencedchanges in antibodies to schizont extract, MSP2 and
MSP3. Significantly more women on SP-CQ than SP-AZ
experienced an increase in antibody response to PfRh2
(8.3 vs 3.6 %; p = 0.05), and in opsonizing antibody to
endothelial-binding IEs (29.6 vs 19.1 %; p = 0.004).
Interestingly, significantly more women on SP-AZ than
SP-CQ experienced an increase in opsonizing antibody to
placental-binding IEs (17.8 vs 12.0 %; p = 0.03; Table 2).
Effect of treatment arm on antibodies at delivery:
adjusted analysis
After adjusting for confounding and interaction variables,
there were no significant differences in antibody levels at
delivery between treatment arms (Table 3). Antibody le-
vels at delivery were associated with rural residence (for
schizont extract, MSP2 and MSP3), and with highlander
heritage (schizont extract and MSP2), all p < 0.05. There
was also a gravidity-dependent increase in opsonizing anti-
body to both endothelial-binding and-placental-binding
IEs, both p < 0.01. Importantly, there was no evidence of
the intervention arm modifying levels of malarial anti-
bodies in higher gravidity women and women from diffe-
rent areas and ethnicity.
Discussion
Malaria prevention during pregnancy reduces exposure
and may affect the acquisition of malaria immunity [4, 5].
In these PNG women, levels of antibody to merozoite and
schizont antigens declined during pregnancy whether
women received single dose of SP-CQ or multiple doses
of SP-AZ.
The reduction in median levels of antibody to schizont
extract and several recombinant merozoite antigens bet-
ween enrolment and delivery may be due to reduced
exposure and/or effective clearance and protection by
SP-AZ or SP-CQ and ITN. Other possible contributions
include the low prevalence of infection and maternal hae-
modilution, as indicated by a concomitant decline in anti-
body to measles haemagglutinin. In contrast, there were
no significant differences in median levels of opsonizing
antibodies to placental-binding IEs or to endothelial-
binding IEs. These observations are consistent with a pre-
vious study from PNG demonstrating maintenance of
opsonizing antibodies during lower force of infection [8].
Antibodies to merozoite antigens may have a shorter
half-life than antibodies to IEs [10]. This could explain
differences observed, if repeated exposure is required to
maintain anti-merozoite antibodies.
There are many different assays for measuring poten-
tially protective anti-malarial antibody. In Ghana, anti-
bodies to recombinant placental-binding P. falciparum
erythrocyte membrane protein 1 (PfEMP1) proteins in-
creased during pregnancy and declined after delivery,
suggesting that these antibody responses are transient in
Fig. 1 Levels of immunoglobulin G (IgG) antibody in PNG pregnant women against Plasmodium falciparum antigens over the course of one pregnancy.
White bars- pregnant women recruited at first antenatal visit, grey bars pregnant women at delivery. Pregnant women on sulfadoxine-pyrimethamine
(SP) and chloroquine (CQ) [N = 304], and on SP and azithromycin (AZ) [N = 277]. a Levels of IgG antibodies to schizont extract, PfRh2, MSP2, MSP3 and
measles antigen presented as arbitrary units. b Levels of opsonising IgG antibodies to variant surface antigens of placental-binding and endothelial-
binding IEs, presented as percentage of THP-1 cells that have ingested IESs (percentage phagocytosis). Wilcoxon signed-rank test, ****p < 0.0001.
Columns represents IQR and error bars shows 95 % CI
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zing antibodies to placental-binding IEs may reflect the
lower force of infection in this study, but lack of decline
in these circumstances suggests that opsonizing anti-
bodies might be more stable than IgG to recombinant
antigens [8]. In Ghana, the levels of antibodies to recom-
binant endothelial-binding PfEMP1 proteins did not vary
during pregnancy [11], similar to the present findings
for opsonizing antibodies to endothelial-binding IEs.
The relative stability of functional opsonizing anti-
bodies even with low force of infection, compared with
IgG directed to recombinant antigens, makes their levels
a potential measure of longer lasting immunity to MiP.
Whether functional properties of antibodies to IEs, in-
cluding opsonizing activity and inhibition of placentalbinding [2] are the best correlates of protective im-
munity requires further exploration. Longitudinal studies
of functional antibodies to merozoites [12] during preg-
nancy would also be of great interest.
Anti-malarial prevention strategies may affect the de-
velopment of pregnancy-associated malaria immunity [5,
13], but in the present study the change in opsonizing
antibody to placental-binding IEs did not differ between
treatment arms, after controlling for confounders and
explanatory variables. The disparity between the current
study and others may be explained by the differences in
endemicity, high ITN coverage in this cohort, and dif-
ferences in assays used. Malaria antibodies vary during
pregnancy [9, 11], and it was observed that analysis at
group level concealed heterogeneity in responses among
Table 2 Changes in antibody responses against P. falciparum
antigens in the Papua New Guinean cohort during the course
of pregnancy
Variable (n) SP + CQ control
arm (n = 304)
SP + AZ intervention
arm (n = 277)
P value
IgG to schizont extract 0.7
Decrease, n (%) 70 (23.2) 67 (24.3)
No change, n (%) 198 (65.6) 184 (66.8)
Increase, n (%) 34 (11.3) 25 (9.1)
IgG to MSP2 0.6
Decrease, n (%) 63 (20.9) 49 (17.8)
No change, n (%) 217 (71.9) 203 (73.6)
Increase, n (%) 22 (7.3) 24 (8.7)
IgG to MSP3 0.8
Decrease, n (%) 55 (18.2) 53 (19.1)
No change, n (%) 220 (72.8) 203 (73.3)
Increase, n (%) 27 (8.9) 21 (7.6)
IgG to PfRh2 0.05
Decrease, n (%) 34 (11.2) 39 (14.1)
No change, n (%) 244 (80.5) 228 (82.3)
Increase, n (%) 25 (8.3) 10 (3.6)
Opsonizing IgG to
E8B-ICAM
0.004
Decrease, n (%) 72 (23.9) 60 (21.7)
No change, n (%) 140 (46.5) 164 (59.2)
Increase, n (%) 89 (29.6) 53 (19.1)
Opsonizing IgG to CS2 0.03
Decrease, n (%) 39 (13.0) 47 (17.0)
No change, n (%) 226 (75.1) 180 (65.2)
Increase, n (%) 36 (12.0) 49 (17.8)
Data represented as numbers and percentage, P-values are also shown
AZ azithromycin, CQ chloroquine, SP sulfadoxine-pyrimethamine
Significant associations (p < 0.05) highlighted in bold
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vidual women’s antibody responses between enrolment
and delivery differed by treatment arm. A greater pro-
portion of women on SP-CQ experienced increases in
antibody to PfRh2 and in opsonizing antibody against
endothelial-binding IEs than women on SP-AZ, con-
sistent with increased exposure associated with the less
effective intervention. Supporting this, in the parent
study SP-AZ decreased parasite prevalence at delivery by
microscopy and placental histology [14]. Although mul-
tiple courses of anti-malarials during pregnancy may de-
crease malaria exposure, the impact on immunity in the
context of low prevalence of infection and high ITN use
appears modest.
In contrast to antibody to endothelial-binding IEs,
levels of opsonizing antibodies to placental-binding IEswere more likely to increase or decrease (rather than
remaining constant) in the SP-AZ arm compared with the
SP-CQ arm, consistent with previous observations [8].
This reflects the complex dynamics of pregnancy-specific
malarial immunity during a single pregnancy [9–11].
Assaying at multiple time points during pregnancy may
assist better evaluation of pregnancy-associated immune
status.
In the adjusted analyses, factors influencing malarial
antibody levels at delivery did not vary between the treat-
ment arms. Increasing gravidity is associated with higher
opsonizing antibodies to IEs consistent with gravidity-
dependent acquisition of pregnancy-specific immunity [2].
Rural women had higher antibodies to schizont extract,
MSP2 and MSP3 than women from urban areas, whereas
highlands-born women tended to have lower antibody
levels to schizont extract and MSP2. These differences,
which are indicative of more malaria exposure with in-
creasing gravidity and in women residing in the rural
areas, and lower exposure in the highlands-born women,
were independent of treatment arm. Anti-malarials could
have a greater impact on malaria immunity in settings of
lower ITN usage and higher prevalence of infection.
The current study may have underestimated potential
benefits of prevention. First, the low malaria prevalence
may have reduced the power to observe any potential im-
pact of different treatment arms on the acquisition of
pregnancy-associated malaria immunity. Second, although
high ITN coverage may reduce the need for intensive
IPTp and, consequently, reduce selection pressure on the
parasites [15, 16], high ITN coverage may have further re-
duced malaria exposure in this study, obscuring a possible
effect of drug regimen on immune responses. Finally, the
time for which women participated varied between three
and six months; earlier implementation of malaria pre-
vention might have had a greater impact on immunity
development. Studies from higher-transmission areas,
spanning most or all of gestation, are more likely to de-
monstrate the impact of malaria prevention on the acqui-
sition of pregnancy-associated malaria immunity.
Conclusions
In conclusion, IPTp with multi-doses of SP-AZ or a
single-dose SP-CQ had similar impacts on pregnancy-
associated malaria immunity, possibly due to the low
prevalence of infection and extensive ITN coverage ob-
served. The decline in merozoite and schizont antibodies
observed between enrolment and delivery supports this.
This study also demonstrated an apparent maintenance
of functional opsonizing antibodies, thought to be im-
portant for prevention of morbidity, which deserves fur-
ther evaluation in other regions and in the context of
other preventive measures to elucidate the optimum
policy in preventing MiP in such regions.
Table 3 Relative antibody responses against P. falciparum antigens at delivery by treatment arm in Madang, PNG, adjusted for confounding and interaction variables
Variables IgG schizont extract IgG PfRh2 IgG MSP2 IgG MSP3 Opsonizing IgG E8B-ICAM Opsonizing IgG CS2
Coeff (95 % Cl) p Coeff (95 % Cl) p Coeff (95 % Cl) p Coeff (95 % Cl) p Coeff (95 % Cl) p Coeff (95 % Cl) p
Intervention arma −3.0 (−13.4, 7.4) 0.6 −3.6 (−10.9, 3.7) 0.3 −7.4 (−17.9, 3.1) 0.2 2.6 (−7.0, 12.2) 0.6 1.0 (−14.2, 16.2) −7.4 (−19.4, 4.5) 0.2
Gravidity
1
2 −2.0 (−8.3, 4.3) 0.5 −4.6 (−9.1, 0.2) 0.06 1.0 (−5.44, 7.42) 0.8 −0.7 (−6.6, 5.1) 0.8 50.3 (42.8, 57.9) <0.0001 9.3 (2.5,16.1) 0.007
3 1.6 (−4.5, 7.6) 0.6 −0.5 (−4.8, 3.8) 0.8 1.9 (−4.3, 8.1) 0.6 5.72 (−0.04, 11.4) 0.06 32.8 (25.6, 40.1) <0.0001 24.3 (17.9, 30.8) <0.0001
Overall bed net use
No
Intermittent −1.8 (−6.0, 2.4) 0.4 −0.5 (−3.4, 2.5) 0.8 −1.6 (−5.9, 2.7) 0.5 0.3 (−5.6, 10.5) 0.9 1.2 (−3.8, 6.2) 0.6 −2.6 (−7.2, 1.9) 0.3
Regular −13.0 (−45.2, 19.2) 0.4 −5.3 (−28.1, 17.6) 0.7 −12.0 (−45.0, 20.9) 0.5 −2.5 (−32.7, 27.6) 0.9 25.4 (−13.1, 63.9) 0.2 −10.6 (−45.0, 23.8) 0.6
Residence
Urban
Peri-urban 0.3 (−8.4, 8.8) 0.9 −1.3 (−7.1, 5.9) 0.7 1.5 (−7.2, 10.2) 0.7 2.0 (−5.9, 10.0) 0.6 2.2 (−10.4, 14.9) 0.4 −1.9 (−11.8, 7.9) 0.7
Rural 8.6 (1.2, 15.9) 0.02 5.0 (−0.2, 10.0) 0.06 8.5 (1.2, 16.0) 0.02 8.5 (1.7, 15.2) 0.01 −4.1 (−14.8, 6.6) 0.7 −0.4 (−8.8, 8.0) 0.9
Migrant 13.0 (−1.3, 27.3) 0.07 −0.1 (−10.1, 10.0) 0.9 13.3 (−1.1, 27.7) 0.07 −1.1 (−14.3, 12.1) 0.9 6.4 (−14.4, 27.3) 0.5 2.7 (−13.7, 19.1) 0.8
Ethnicity
Madang/Morobe
Sepik −4.7 (−11.0, 11.0) 0.2 0.3 (−4.7, 5.2) 0.9 −5.4 (−12.6, 1.7) 0.1 1.7 (−4.8, 8.2) 0.6 −1.6 (−11.9, 8.7) 0.8 4.7 (−12.8, 3.4) 0.2
Highlands −12.3 (−21.9, −2.6) 0.01 −0.5 (−7.2, 6.2) 0.9 −10.9 (−20.6, −1.2) 0.03 −1.0 (−9.9, 7.7) 0.82 −3.7 (−17.7, 10.4) 0.8 −6.4 (−17.4, 4.7) 0.4
Others −4.4 (−13.9, 5.2) 0.4 −2.5 (−9.3, 4.2) 0.5 −7.5 (−17.0, 2.2) 0.1 1.3 (−7.5, 10.1) 0.8 −2.4 (−16.5, 11.7) 0.9 −2.6 (13.5, 8.3) 0.6
SP-AZ-graviditya
1
2 −5.6 (−14.77, 3.56) 0.2 7.1 (0.57, −13.56) 0.1 −6.5 (−15.90, 2.87) 0.2 −3.5 (−12.10, 5.06) 0.4 −6.5 (−17.48, 4.50) 0.3 −0.3 (−10.1, 9.5) 1.0
3 −5.5 (−14.3, 5.6) 0.3 1.2 (−5.1, 7.5) 0.7 −7.6 (−16.7, 1.5) 0.1 −7.5 (−15.8, 0.8) 0.08 −5.6 (−16.2, 5.0) 0.3 0.01 (−9.5, 9.5) 1.0
SP-AZ-residencea
Urban
Peri-urban 5.0 (−7.7, 17.6) 0.4 2.1 (−6.7, 11.0) 0.6 2.9 (−9.9, 15.7) 0.7 −1.1 (−12.8, 10.6) 0.9 −8.2 (−26.8, 10.3) 0.4 8.4 (−6.1, 23.0) 0.3
Rural 2.7 (−8.2, 13.6) 0.6 2.7 (−5.0, 10.3) 0.5 7.5 (−3.5, 18.5) 0.2 −3.9 (−14.0, 6.1) 0.4 −2.8 (−18.7, 13.1) 0.7 7.7 (−4.8, 2.2) 0.2
Migrant 1.2 (−19.5, 21.9) 0.9 7.2 (−7.3, 21.7) 0.3 −5.63 (−26.55, 15.29) 0.6 3.7 (−15.43, 22.78) 0.7 −17.6 (−47.8, 12.6) 0.3 0.5 (−23.3, 24.2) 1.0
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Table 3 Relative antibody responses against P. falciparum antigens at delivery by treatment arm in Madang, PNG, adjusted for confounding and interaction variables
(Continued)
SP-AZ-ethnicitya
Madang/Morobe
Sepik 0.02 (−11.0, 11.00) 1.0 1.9 (−5.9, 9.6) 0.6 5.1 (−6.0, 16.2) 0.4 −4.6 (−14.7, 5.6) 0.4 −1.6 (−17.7, 14.4) 0.8 11.5 (−1.1, 24.1) 0.07
Highlands −1.0 (−16.0, 14.0) 0.9 −1.3 (−11.8, 9.2) 0.8 1.6 (−13.6, 16.7) 0.8 −5.53 (−19.4, 8.3) 0.4 −2.8 (−24.7, 19.1) 0.8 6.7 (−10.6, 23.9) 0.5
Others 0.5 (−14.2, 13.1) 0.9 3.3 (−6.3, 12.9) 0.5 6.6 (−7.2, 20.5) 0.4 −3.6 (−16.2, 9.0) 0.6 −1.0 (−21.1, 19.2) 0.9 −3.6 (−19.3, 12.1) 0.7
Data represented as coefficients and 95 % confidence interval (Multiple linear regression models), P-values are also shown
SP sulfadoxine-pyrimethamine, AZ azithromycin, against control group (SP-CQ), CQ chloroquine
aRefers to relative antibody responses in intervention group (SP-AZ). A positive coefficient implies an increase of antibody levels. A negative coefficient implies a decrease of antibody levels. Significant associations
(p < 0.05) highlighted in bold
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SP: Sulfadoxine-pyrimethamine; MIP: Malaria in pregnancy; IPTp: Intermittent
preventive therapy during pregnancy; ITN: Insecticide-treated bed nets;
PNG: Papua New Guinea; ANC: First antenatal visit; CQ: Chloroquine;
AZ: Azithromycin; LMS: Light microscopy; qPCR: Quantitative polymerase
chain reaction; IgG: Immunoglobulin G; ELISA: Enzyme-lined immunosorbent
assay; Ies: Infected erythrocytes; PfEMP1: P. falciparum erythrocyte membrane
protein 1.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conceived and designed the experiment: SJR, GVB, IM Performed the
experiments: AT, WH. Analysed the data: AT, SR. Contributed reagents/
materials/analysis tools: AT, SJR, IM, PMS, HU, LMR. Wrote the paper: AT, GVB,
SJR. All authors read and approved the final manuscript.
Acknowledgements
We thank the pregnant women for their participants in the study. We are
grateful to Dr. Maria Ome-Kaius, Dr. Regina Wangnapi and Dr. Sarah Hanieh
for clinical support, and Dr. Alex Umbers, Dr. Leanne Robinson, Elvin Lufele,
Paula Samol, and other staff for laboratory support. We would also like to
acknowledge Prof James Beeson and Christine Langer for providing merozoite
antigens, MSP 3 and PfRh2, and Prof Robin Anders for merozoite antigen, MSP2.
Funding
This study was supported by National Health and Medical Research council
of Australia awarded to SJR and GVB, Grant number: 10244441. Sample
collection was supported in part by Malaria in Pregnancy Consortium, which
receives funding from the Bill and Melinda Gates Foundation. The funders
had no role in study design, data collection and analysis, decision to publish
or preparation of the manuscript.
Author details
1University of Melbourne, Department of Medicine (Royal Melbourne
Hospital), Melbourne, VIC, Australia. 2Victorian Infectious Diseases Service, The
Doherty Institute, Melbourne, VIC, Australia. 3Papua New Guinea Institute of
Medical Research, Goroka, Papua New Guinea. 4The Walter and Eliza Hall
Institute of Medical Research, Melbourne, VIC, Australia. 5Barcelona Centre for
International Health Research (CRESIB), Barcelona, Spain. 6The Nossal Institute
for Global Health, The University of Melbourne, Melbourne, VIC, Australia.
Received: 3 December 2014 Accepted: 20 May 2015
References
1. Brabin BJ. An analysis of malaria in pregnancy in Africa. Bull World Health
Organ. 1983;61:1005–16.
2. Fried M, Nosten F, Brockman A, Brabin BJ, Duffy PE. Maternal antibodies
block malaria. Nature. 1998;395:851–2.
3. Ataíde R, Mwapasa V, Molyneux ME, Meshnick SR, Rogerson SJ. Antibodies
that induce phagocytosis of malaria infected erythrocytes: effect of HIV
infection and correlation with clinical outcomes. PLoS One. 2011;6:e22491.
4. Feng G, Simpson JA, Chaluluka E, Molyneux ME, Rogerson SJ. Decreasing
burden of malaria in pregnancy in Malawian women and its relationship to
use of intermittent preventive therapy or bed nets. PLoS One.
2010;5:e12012.
5. Aitken EH, Mbewe B, Luntamo M, Kulmala T, Beeson JG, Ashorn P, et al.
Antibody to P. falciparum in pregnancy varies with intermittent preventive
treatment regime and bed net use. PLoS One. 2012;7:e29874.
6. Intermittent preventive treatment with Azithromycin-containing Regimens in
pregnant women in Papua New Guinea (IPTp in PNG) [http://clinicaltrials.gov/
show/NCT01136850]
7. Bulmer JN, Rasheed FN, Francis N, Morrison L, Greenwood BM. Placental
malaria. I Pathological classification. Histopathology. 1993;22:211–8.
8. Teo A, Hasang W, Randall LM, Feng G, Bell L, Unger H, et al. Decreasing
malaria prevalence and its potential consequences for immunity in
pregnant women. J Infect Dis. 2014;210:1444–55.9. Aitken EH, Mbewe B, Luntamo M, Maleta K, Kulmala T, Friso MJ, et al.
Antibodies to chondroitin sulfate A-binding infected erythrocytes: dynamics
and protection during pregnancy in women receiving intermittent
preventive treatment. J Infect Dis. 2010;201:1316–25.
10. Fowkes FJ, McGready R, Cross NJ, Hommel M, Simpson JA, Elliott SR, et al.
New insights into acquisition, boosting, and longevity of immunity to
malaria in pregnant women. J Infect Dis. 2012;206:1612–21.
11. Ampomah P, Stevenson L, Ofori MF, Barfod L, Hviid L. Kinetics of B cell
responses to Plasmodium falciparum erythrocyte membrane protein 1 in
Ghanaian women naturally exposed to malaria parasites. J Immunol.
2014;192:5236–44.
12. Osier FH, Feng G, Boyle MJ, Langer C, Zhou J, Richards JS, et al. Opsonic
phagocytosis of Plasmodium falciparum merozoites: mechanism in human
immunity and a correlate of protection against malaria. BMC Med.
2014;12:108.
13. Staalsoe T, Shulman CE, Dorman EK, Kawuondo K, Marsh K, Hviid L. Intermittent
preventive sulfadoxine-pyrimethamine treatment of primigravidae reduces levels
of plasma immunoglobulin G, which protects against pregnancy-associated
Plasmodium falciparum malaria. Infect Immun. 2004;72:5027–30.
14. Unger HW, Ome-Kaius M, Wangnapi RA, Umbers AJ, Hanieh S, Suen CS,
et al. Sulphadoxine-pyrimethamine plus azithromycin for the prevention of
low birthweight in Papua New Guinea: a randomised controlled trial.
BMC Med. 2015;13:9.
15. Ndyomugyenyi R, Clarke SE, Hutchison CL, Hansen KS, Magnussen P.
Efficacy of malaria prevention during pregnancy in an area of low and
unstable transmission: an individually-randomised placebo-controlled trial
using intermittent preventive treatment and insecticide-treated nets in the
Kabale Highlands, southwestern Uganda. Trans R Soc Trop Med Hyg.
2011;105:607–16.
16. Menendez C, Bardaji A, Sigauque B, Romagosa C, Sanz S, Serra-Casas E, et al.
A randomized placebo-controlled trial of intermittent preventive treatment
in pregnant women in the context of insecticide treated nets delivered
through the antenatal clinic. PLoS One. 2008;3:e1934.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
